BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Raludotatug Deruxtecan readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Raludotatug Deruxtecan\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04707248-2696@assetmemo.bio
DTSTAMP:20261121T005928Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Raludotatug Deruxtecan: Phase 1 readout est. (NCT04707248)
DESCRIPTION:Raludotatug Deruxtecan\, phase 1.\nStudy: A Study of DS-6000a i
 n Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors\nEstimate
 d primary completion: 30 December 2026. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/raludotatug-deruxtecan#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT04707248
URL:https://assetmemo.bio/drug/raludotatug-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06161025-2696@assetmemo.bio
DTSTAMP:20261121T005928Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Raludotatug Deruxtecan: Phase 2/3 readout est. (NCT06161025)
DESCRIPTION:Raludotatug Deruxtecan\, phase 2/3.\nStudy: A Study of Raludota
 tug Deruxtecan (R-DXd) in Subjects With Platinum-resistant\, High-grade Ov
 arian\, Primary Peritoneal\, or Fallopian Tube Cancer\nEstimated primary c
 ompletion: 29 February 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/raludotatug-deruxtecan#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06161025
URL:https://assetmemo.bio/drug/raludotatug-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06843447-2696@assetmemo.bio
DTSTAMP:20261121T005928Z
DTSTART;VALUE=DATE:20290327
DTEND;VALUE=DATE:20290328
SUMMARY:Raludotatug Deruxtecan: Phase 1/2 readout est. (NCT06843447)
DESCRIPTION:Raludotatug Deruxtecan\, phase 1/2\, Ovarian Cancer.\nStudy: A 
 Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK
 -5909-003).\nEstimated primary completion: 27 March 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/raludotatug-deruxtecan#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06843447
URL:https://assetmemo.bio/drug/raludotatug-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07791732-2696@assetmemo.bio
DTSTAMP:20261121T005928Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:Raludotatug Deruxtecan: Phase 3 readout est. (NCT07791732)
DESCRIPTION:Raludotatug Deruxtecan\, phase 3\, Ovarian Cancer.\nStudy: A St
 udy of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maint
 enance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer 
 (REJOICE-Ovarian03)\nEstimated primary completion: 1 July 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/raludotatug-deruxtecan#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07791732
URL:https://assetmemo.bio/drug/raludotatug-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04938817-2696@assetmemo.bio
DTSTAMP:20261121T005928Z
DTSTART;VALUE=DATE:20291210
DTEND;VALUE=DATE:20291211
SUMMARY:Raludotatug Deruxtecan: Phase 1/2 readout est. (NCT04938817)
DESCRIPTION:Raludotatug Deruxtecan\, phase 1/2.\nStudy: Safety and Efficacy
  Study of Investigational Agents as Monotherapy or in Combination With Pem
 brolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung 
 Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)\
 nEstimated primary completion: 10 December 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/raludotatug-deruxtecan#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT04938817
URL:https://assetmemo.bio/drug/raludotatug-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06660654-2696@assetmemo.bio
DTSTAMP:20261121T005928Z
DTSTART;VALUE=DATE:20291230
DTEND;VALUE=DATE:20291231
SUMMARY:Raludotatug Deruxtecan: Phase 2 readout est. (NCT06660654)
DESCRIPTION:Raludotatug Deruxtecan\, phase 2.\nStudy: A Study of Raludotatu
 g Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOIC
 E-PanTumor01)\nEstimated primary completion: 30 December 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/raludotatug-deruxtecan#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06660654
URL:https://assetmemo.bio/drug/raludotatug-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07743164-2696@assetmemo.bio
DTSTAMP:20261121T005928Z
DTSTART;VALUE=DATE:20310831
DTEND;VALUE=DATE:20310901
SUMMARY:Raludotatug Deruxtecan: Phase 3 readout est. (NCT07743164)
DESCRIPTION:Raludotatug Deruxtecan\, phase 3\, Ovarian Cancer.\nStudy: A Cl
 inical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab
  in Participants With Ovarian Cancer Who Have Progressed During Treatment 
 With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGO
 T-ov107/GOG-3142 / REJOICE-Ovarian05)\nEstimated primary completion: 31 Au
 gust 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/raludotatu
 g-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07743164
URL:https://assetmemo.bio/drug/raludotatug-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06780098-2696@assetmemo.bio
DTSTAMP:20261121T005928Z
DTSTART;VALUE=DATE:20320302
DTEND;VALUE=DATE:20320303
SUMMARY:Raludotatug Deruxtecan: Phase 2 readout est. (NCT06780098)
DESCRIPTION:Raludotatug Deruxtecan\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Substudy 01I: A Study of Investigational Agents in Participants Wi
 th Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC)
  (MK-3475-01I/KEYMAKER-U01I)\nEstimated primary completion: 2 March 2032. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/raludotatug-deruxteca
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 780098
URL:https://assetmemo.bio/drug/raludotatug-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06780085-2696@assetmemo.bio
DTSTAMP:20261121T005928Z
DTSTART;VALUE=DATE:20320312
DTEND;VALUE=DATE:20320313
SUMMARY:Raludotatug Deruxtecan: Phase 2 readout est. (NCT06780085)
DESCRIPTION:Raludotatug Deruxtecan\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: A Study of Investigational Agents in Participants With Previously 
 Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-0
 1H/KEYMAKER-U01)\nEstimated primary completion: 12 March 2032. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/raludotatug-deruxtecan#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06780085
URL:https://assetmemo.bio/drug/raludotatug-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07776691-2696@assetmemo.bio
DTSTAMP:20261121T005928Z
DTSTART;VALUE=DATE:20320319
DTEND;VALUE=DATE:20320320
SUMMARY:Raludotatug Deruxtecan: Phase 3 readout est. (NCT07776691)
DESCRIPTION:Raludotatug Deruxtecan\, phase 3\, Ovarian Cancer.\nStudy: A St
 udy of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Ma
 intenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-0
 06\, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)\nEstimated primary complet
 ion: 19 March 2032. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/r
 aludotatug-deruxtecan#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07776691
URL:https://assetmemo.bio/drug/raludotatug-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
